Latest News of SRPT
Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?
By Yahoo! Finance |
6 days ago
A recent article analyzes Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against other top revenue growth stocks recommended by analysts. It discusses the impact of recent Fed rate cuts and market trends....
Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity
By Yahoo! Finance |
2 weeks ago
Insider Monkey's recent article highlights the 16 Best Mid Cap Growth Stocks, focusing on Sarepta Therapeutics Inc. (NASDAQ:SRPT)....
Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds' Top Biotech Stock Picks
By Yahoo! Finance |
3 weeks ago
The article discusses the risks and challenges of investing in biotechnology stocks, highlighting the importance of thorough research and diversification. It also evaluates Sarepta Therapeutics, Inc. ...
-
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
By Yahoo! Finance | 4 weeks agoA list of top biotech stocks to invest in was compiled, focusing on Sarepta Therapeutics, Inc. Amid a growing biotechnology industry, AI-driven drug discovery and promising outlooks for companies like...
-
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
By Yahoo! Finance | 2 months agoSarepta Therapeutics (SRPT) has gained 51% year-to-date, with a closing price of $146.03 on July 29th. Analysts are bullish on SRPT, expecting significant growth driven by the successful launch of Ele...
-
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
By Yahoo! Finance | 3 months agoRyan Brown, EVP and General Counsel of Sarepta Therapeutics Inc (NASDAQ:SRPT), sold 38,957 shares on June 25, 2024. The insider now holds 17,129 shares....
-
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 3 months agoSarepta Therapeutics Inc. has obtained expanded US approval for its gene therapy to treat more children with a fatal muscle disease, despite lacking clear evidence of its benefits in clinical trials....